Analysts Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Target Price at $131.30

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have received an average rating of “Moderate Buy” from the eleven analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $134.30.

ORKA has been the subject of a number of research reports. UBS Group upped their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Piper Sandler restated an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Guggenheim set a $200.00 target price on Oruka Therapeutics and gave the stock a “buy” rating in a report on Monday, April 27th. BTIG Research reissued a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a research note on Thursday, May 14th. Finally, Stifel Nicolaus raised their price target on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th.

Oruka Therapeutics Trading Up 6.1%

ORKA traded up $5.11 on Tuesday, hitting $88.24. 1,222,710 shares of the company’s stock traded hands, compared to its average volume of 1,192,120. The company’s 50 day simple moving average is $69.41 and its 200-day simple moving average is $49.92. The firm has a market cap of $5.32 billion, a price-to-earnings ratio of -45.52 and a beta of -0.35. Oruka Therapeutics has a one year low of $12.84 and a one year high of $97.78.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, equities analysts anticipate that Oruka Therapeutics will post -2.06 EPS for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,947 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.28, for a total transaction of $550,568.16. Following the sale, the insider owned 32,718 shares of the company’s stock, valued at $2,266,703.04. This represents a 19.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $69.69, for a total transaction of $120,494.01. Following the transaction, the chief executive officer owned 925,580 shares of the company’s stock, valued at $64,503,670.20. This trade represents a 0.19% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 185,407 shares of company stock valued at $11,636,307. 23.49% of the stock is owned by company insiders.

Institutional Trading of Oruka Therapeutics

Several hedge funds have recently made changes to their positions in ORKA. Fairmount Funds Management LLC raised its position in Oruka Therapeutics by 9.9% during the third quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after purchasing an additional 333,340 shares during the period. Secure Asset Management LLC purchased a new position in shares of Oruka Therapeutics in the 4th quarter worth approximately $2,475,000. Avoro Capital Advisors LLC purchased a new position in shares of Oruka Therapeutics in the 3rd quarter worth approximately $25,640,000. Moody Aldrich Partners LLC bought a new position in shares of Oruka Therapeutics during the 4th quarter valued at approximately $3,844,000. Finally, Commodore Capital LP increased its position in shares of Oruka Therapeutics by 23.5% during the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock valued at $33,711,000 after purchasing an additional 333,340 shares during the last quarter. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.